Edition:
United States

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

402.60INR
20 Jul 2017
Change (% chg)

Rs-14.35 (-3.44%)
Prev Close
Rs416.95
Open
Rs418.90
Day's High
Rs419.90
Day's Low
Rs399.20
Volume
4,114,815
Avg. Vol
3,049,128
52-wk High
Rs438.85
52-wk Low
Rs232.17

BION.NS

Chart for BION.NS

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for BION.NS.

Overall

No Ratios Available.

Financials

  BION.NS Industry Sector
P/E (TTM): -- 212.65 15.78
EPS (TTM): -- -- --
ROI: -- -7.61 -8.29
ROE: -- -9.04 -7.91

BRIEF-FDA oncologic drugs advisory committee unanimously recommends approval of Mylan and Biocon's proposed biosimilar Trastuzumab

* FDA oncologic drugs advisory committee unanimously recommends approval of Mylan and Biocon's proposed biosimilar Trastuzumab

Jul 13 2017

BRIEF-Biocon allots bonus shares in 2:1 ratio

* Says allotment in the ratio of 2:1 Source text: http://bit.ly/2rIfgbq Further company coverage:

Jun 19 2017

BRIEF-U.S. FDA issues form 483 to Biocon Bangalore facility

* FDA issues form 483 dated april 7 to Biocon Bangalore facility Source text for Eikon: (http://bit.ly/2pYI4Kt) Further company coverage:

May 09 2017

BRIEF-Biocon seeks members' nod for issue of bonus shares

* Seeks members' nod for increase in authorize share capital to INR 3 billion Source text for Eikon: Further company coverage:

May 05 2017

India watchdog orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 27 2017

UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug

MUMBAI, April 27 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 27 2017

India's antitrust watchdog orders probe into Roche cancer drug

MUMBAI, April 26 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 26 2017

BRIEF-Biocon to consider issue of bonus shares

* Says proposal to consider and recommend issue of bonus shares Source text for Eikon: Further company coverage:

Apr 24 2017

BRIEF-Biocon reaffrims guidance of $200 mln in revenue from biosimilars in FY19

* Says reaffrims guidance of US $200 million in revenue from biosimilars in FY19 Source text - (http://bit.ly/2nztIMx) Further company coverage:

Mar 14 2017

Mylan deal clears path for biosimilar copy of Roche's Herceptin

LONDON Generic drugmaker Mylan said on Monday it had reached a settlement with Roche providing "a clear pathway" for the launch of its biosimilar version of the Swiss company's top-selling breast cancer drug Herceptin in major markets.

Mar 13 2017

Earnings vs. Estimates

No consensus analysis data available.